Semaglutide Side Effects: What the Trials Actually Report

Semaglutide has the longest track record of any GLP-1 used for weight management, which means its side-effect profile is also the best-documented. This guide reports what the pivotal trials and a dedicated safety meta-analysis actually found — not what a forum thread claims.

Gastrointestinal effects, again the dominant category

In semaglutide's pivotal 68-week weight-management trial, gastrointestinal events — nausea, diarrhea, vomiting and constipation — were the most frequently reported adverse events, and they were more common than on placebo¹. A systematic review and meta-analysis focused specifically on semaglutide's efficacy and safety in obesity without diabetes reaches the same conclusion across the pooled trial evidence: GI effects dominate the side-effect profile, generally mild to moderate in severity and more frequent during dose escalation². This is the same pattern reported for tirzepatide — it is a class effect of GLP-1 receptor agonism, not a quirk of one molecule.

Discontinuation rates, by the numbers

In the pivotal trial, more participants on semaglutide discontinued treatment due to an adverse event than on placebo, with GI events cited as the leading reason¹. As with tirzepatide, that is a real, non-zero number — and also not the majority outcome, since most trial participants remained on treatment for the full study period. If your body's reaction hasn't eased after the first several weeks on a given dose, you are not the only person for whom that happened in the trial data.

The long-view safety data: SELECT

Because Wegovy has been studied specifically for cardiovascular outcomes, there is unusually strong long-view safety evidence: the SELECT trial followed over 17,000 adults with cardiovascular disease and overweight or obesity (without diabetes) on semaglutide for a median of about three years and found a reduction in major adverse cardiovascular events compared with placebo, with a safety profile consistent with semaglutide's established GI-effect pattern³. That is one of the longest and largest safety datasets behind any GLP-1, and it is specific to the FDA-approved brand product — not automatically transferable to a compounded version of the same molecule, which is why pharmacy verification matters regardless of which molecule you choose.

What the label flags beyond GI effects

Semaglutide's FDA labeling carries the same class-level warnings as tirzepatide's: a boxed warning about thyroid C-cell tumor risk seen in rodent studies (unconfirmed in humans, but screened for at intake), plus warnings for pancreatitis, gallbladder disease, and hypoglycemia risk when combined with insulin or a sulfonylurea. What the RCT meta-analyses and large real-world cohorts actually show behind those last two warnings — a confirmed gallbladder risk, and a pancreatitis picture more nuanced than the label alone suggests — is covered in full in GLP-1s, pancreatitis and gallbladder risk. A provider's clinical review — a scored factor in our methodology — is where this screening is actually supposed to happen, not a step to shop past for a lower price. Two other areas worth knowing the real evidence on: hair loss on a GLP-1, and pregnancy, fertility and breastfeeding, where the guidance turns out to depend on details most people never hear.

What this means before you buy

Expect GI symptoms during titration, expect them to ease as your dose stabilizes, and know that stopping because it doesn't ease is a documented outcome for a real minority, not evidence something unusual happened to you specifically. Follow the labeled titration schedule rather than a faster provider-set pace, and use a provider with real clinician oversight. For the molecule-vs-molecule tradeoff on both efficacy and price, see semaglutide vs tirzepatide value; if you're weighing whether to keep paying for treatment at all, see what happens when you stop a GLP-1. Not medical advice — see our medical disclaimer and talk to a clinician about your own history.